AGXT2 impacts the nitric oxide (NO) pathway through the competitive inhibition of NOS by ADMA; as a result, AGXT2 can regulate blood pressure and be related to endothelial dysfunction leading to cardiovascular disease (Yoshino et al. 2021; Rochette et al. 2013). Here, AGXT2 is linked to cardiovascular disorder.